Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 4/2016

01-12-2016 | Images

Knuckle Pigmentation: A Clue to Systemic Illness

Authors: Arjun Lakshman, Ram V. Nampoothiri, Sreejesh Sreedharanunni, Pankaj Malhotra, Subhash Varma

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 4/2016

Login to get access

Excerpt

A 50-year-old female, consuming mixed non-vegetarian diet, presented to our out-patient department with easy fatigability, tiredness and dyspnea of 3 months duration. On examination she had severe pallor but systemic examination of the cardiovascular, respiratory, gastrointestinal and neurological systems were within normal limits. Detailed general examination revealed hyperpigmentation of skin over the knuckles of both hands (Fig. 1). Investigations showed hemoglobin of 73 g/L with mean corpuscular volume (MCV) of 116.7 fL, mean corpuscular hemoglobin of 38.8 pg, mean corpuscular hemoglobin concentration of 38.8 % and red cell distribution width of 30.6 %. She also had mild thrombocytopenia (137 × 105/µL). Total leukocyte count was 4100/µL and reticulocyte count was 4 % (Corrected reticulocyte count—1.95 %). Peripheral smear examination showed marked anisopoikilocytosis with macroovalocytes and hypersegmented neutrophils (Fig. 2). Serum lactate dehydrogenase (LDH) was 840 IU/L (normal <480 IU/L). Serum chemistries were within the normal range. Her plasma cyanocobalamin was 144 pg/mL (normal: 187–883 pg/mL). Gastroduodenoscopy and antral biopsy showed features of atrophic gastritis. Her serum tested positive for anti-parietal cell antibody, hence confirming the diagnosis of addisonian pernicious anemia. She symptomatically improved with parenteral hydroxycobalamine—1000 µg intra muscular (im) injection given every third day for seven injections. Her hemoglobin at 1 month follow up improved to 94 g/day and MCV 100.1 fl with improvement in thrombocytopenia (256 × 105/µL). She was put on lifelong vitamin B12 prophylaxis (1000 µg im every month) and asked to follow up yearly with complete blood count and red cell indices.
Literature
1.
go back to reference Hvas AM, Nexo E (2006) Diagnosis and treatment of vitamin B12 deficiency—an update. Haematologica 91(11):1506–1512PubMed Hvas AM, Nexo E (2006) Diagnosis and treatment of vitamin B12 deficiency—an update. Haematologica 91(11):1506–1512PubMed
4.
go back to reference Aaron S, Kumar S, Vijayan J, Jacob J, Alexander M, Gnanamuthu C (2005) Clinical and laboratory features and response to treatment in patients presenting with vitamin B12 deficiency-related neurological syndromes. Neurol India 53(1):55–58; discussion 59 Aaron S, Kumar S, Vijayan J, Jacob J, Alexander M, Gnanamuthu C (2005) Clinical and laboratory features and response to treatment in patients presenting with vitamin B12 deficiency-related neurological syndromes. Neurol India 53(1):55–58; discussion 59
5.
go back to reference Agrawala R, Sahoo S, Choudhury A, Mohanty B, Baliarsinha A (2013) Pigmentation in vitamin B12 deficiency masquerading Addison’s pigmentation: a rare presentation. Indian J Endocrinol Metab 17(7):254CrossRef Agrawala R, Sahoo S, Choudhury A, Mohanty B, Baliarsinha A (2013) Pigmentation in vitamin B12 deficiency masquerading Addison’s pigmentation: a rare presentation. Indian J Endocrinol Metab 17(7):254CrossRef
Metadata
Title
Knuckle Pigmentation: A Clue to Systemic Illness
Authors
Arjun Lakshman
Ram V. Nampoothiri
Sreejesh Sreedharanunni
Pankaj Malhotra
Subhash Varma
Publication date
01-12-2016
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 4/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-016-0690-y

Other articles of this Issue 4/2016

Indian Journal of Hematology and Blood Transfusion 4/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine